Prostatic artery embolization is a minimally invasive treatment procedure for benign prostatic hyperplasia. It helps reduce prostate size and addresses symptoms such as frequent urination and slow urine flow without surgically removing the prostate. The procedure involves blocking blood flow to the prostate using small beads or coils threaded via catheter from the groin area. This causes the prostate tissue to shrink and provides effective relief from BPH symptoms. The advantages of PAE over other treatment options include shorter hospital stay, faster recovery time, and preservation of sexual function and urinary continence. The global Prostatic Artery Embolization Market is estimated to be valued at US$ 235 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increased adoption of minimally invasive treatment procedures is one of the key trends driving the growth of the prostatic artery embolization market. Minimally invasive procedures like PAE offer advantages over invasive surgical treatments. With advancements in catheterization and embolization devices, PAE has become a safer and more reproducible technique. It is gaining acceptance as an early intervention for symptomatic BPH patients who want to avoid surgery. Growing awareness among clinicians and patients about PAE and its benefits compared to TURP is also contributing to the rising uptake of this minimally invasive option for treating enlarged prostate. Additionally, favorable reimbursement and regulatory approvals in major markets will further aid market expansion over the forecast period.
Segment Analysis
The global prostatic artery embolization market can be segmented based on procedure, end user, and geography. Based on procedure, the market is divided into single prostatic artery embolization and bilateral prostatic artery embolization. Currently, bilateral prostatic artery embolization dominates the market as it is considered more effective than single prostatic artery embolization for treating benign prostatic hyperplasia (BPH). The bilateral procedure blocks blood flow to both lobes of the prostate gland, providing better symptom relief and clinical improvement for patients with BPH.
Key Takeaways
The Global Prostatic Artery Embolization Market Size is expected to witness high growth.
Regional analysis: North America region currently dominates the market and is expected to maintain its leading position during the forecast period. This is mainly attributed to the growing geriatric population suffering from BPH, faster adoption of minimally invasive procedures for BPH treatment, and favorable reimbursement policies in the region.
Key players: Key players operating in the prostatic artery embolization market are Ingersoll-Rand plc (Nexia), Vivint, Inc., Protection One Alarm Monitoring, Inc., The ADT Corporation, Telus Communications, Frontpoint Security Solutions, AT&T Inc., Johnson Controls, Inc., Comcast Corporation, Charter Communications (TWC).
For More Insights, Read: https://www.newswirestats.com/prostatic-artery-embolization-market-size-share-and-growth-forecast-2024-2030/
COVID-19 Impact Analysis on Prostatic Artery Embolization Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2020-2027.
The major players in the prostatic artery embolization market include Merit Medical Systems, Boston Scientific, Mentice, Siemens Healthcare, Terumo Europe NV, General Electric Company, Tampa General Hospital, UNC Health Care, Henry Ford, and Spire Healthcare.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Prostatic Artery Embolization Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/prostatic-artery-embolization-market/download-sampleMarket DynamicsExpanding geriatric population, rising prevalence of benign prostatic hyperplasia, and growing preference for minimally invasive treatments drive the growth of the global prostatic artery embolization market.
Benign prostatic hyperplasia is a common condition in the aging population that results in bothersome symptoms and decreased quality of life.
Benign prostatic hyperplasia affects over 50% of men by the age of 60 years and up to 80% of men older than 70 years, and its burden is increasing as the population ages.
However, PAE-treated patients may experience nausea, pelvic pain, and frequent urination, which is likely to refrain them from opting for this treatment.The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis.
